Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392033 | 0.82 | KDM4E (0.39) | NPC1KDM4EALDH1A1 | |
| SCHEMBL4394090 | 0.76 | NPC1 (0.35) | ADRA2AADRA2BADRA2CPLAUNPC1 | |
| SCHEMBL4383276 | 0.73 | S1PR1 (0.37) | ADRA2AADRA2BADRA2CPLAUNPC1 | |
| SCHEMBL15335189 | 0.72 | SMN1; SMN2 (0.35) | KDM4EALDH1A1DYRK1A | |
| SCHEMBL17502186 | 0.71 | HTT (0.41) | KDM4EALDH1A1DYRK1A | |
| SCHEMBL40864 | 0.70 | KDM4E (0.46) | ADRA2AADRA2BADRA2CPLAUNPC1 | |
| SCHEMBL4383311 | 0.69 | GBA1 (0.40) | ADRA2AADRA2BADRA2CPLAUNPC1 | |
| SCHEMBL4391392 | 0.68 | DYRK1A (0.45) | NPC1KDM4EALDH1A1DYRK1A | |
| SCHEMBL31171647 | 0.65 | — | — | |
| SCHEMBL1241251 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084608-B2 | 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2128165-A1 | 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof | Shin-Etsu Chemical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | CBR3, TST, HRH3 | ADRA2A 2089/4885ADRA2B 1610/4885ADRA2C 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.